- Abeona Therapeutics Provides Regulatory Update on Pz-cel
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Announces $50 Million Credit Facility
- Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
- Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
- Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Abeona Therapeutics Inc (ABEO:NAQ) closed at 3.26, 15.19% above the 52 week low of 2.83 set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.27 |
---|---|
High | 3.38 |
Low | 3.20 |
Bid | 3.29 |
Offer | 3.31 |
Previous close | 3.19 |
Average volume | 1.28m |
---|---|
Shares outstanding | 27.36m |
Free float | 25.41m |
P/E (TTM) | -- |
Market cap | 87.26m USD |
EPS (TTM) | -2.59 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼